linjc16/ctgov huggingface dataset:
Feasibility Study of an Intervention Therapeutic Education for Patients Treated With Androgen Deprivation

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to build and assess the feasibility of a therapeutic education program, constructed in collaboration with the urologists of the University Hospital of Saint Etienne. The aim of this therapeutic education program is to delay the onset or to reduce the amplitude of the development of insulin resistance and side effects of androgen deprivation therapy in patients treated with androgen deprivation in the context of an evolutive prostate cancer.

Official Title
-----------------
Feasibility Study of an Intervention Therapeutic Education for Patients Treated With Androgen Deprivation

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Behavioral: therapeutic education program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients supported in consultation Urology at the University Hospital North Saint Etienne. Aged over 18 years Having an evolutive prostate cancer Patient treated with LHRH agonist for at least 6 months - Affiliated with the national health insurance system And having completed the worksheet informed consent to participate in the program. Exclusion Criteria: Refusal of participation, protected or under guardianship patients. Patients unable to understand the study or unable to follow the educational sessions. Patient (s) with documented cognitive or psychiatric history. Geographical remotness (more than 100 Kms.)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: therapeutic education program<br>patients attend three sessions of therapeutic education | Behavioral: therapeutic education program<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients who refused to participate |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients in all sessions |  | 6 months | 
| Number of withdrawals |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
therapeutic patient education, insulinoresistance, empowerment, prostate cancer, oral endocrine therapy, side effects
Arterial Inflammation and E-Cigarettes

Study Overview
=================
Brief Summary
-----------------
Arterial inflammation will be compared using PET scanning in 3 groups: 1) Non-smokers, 2) Tobacco cigarette smokers, 3) Electronic cigarette users.

Detailed Description
-----------------
Qualified participants will undergo a singe PET/CT to detect arterial inflammation.

Official Title
-----------------
Arterial Inflammation and E-Cigarettes

Conditions
-----------------
Arterial Inflammation

Intervention / Treatment
-----------------
* Other: No drug or device, only a test. The test is called a PET/CT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy Nonsmokers OR Daily e-cigarette user OR Daily tobacco cigarette smoker Exclusion Criteria: Cardiac disease Respiratory Disease Diabetes mellitus

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Healthy control<br>Will undergo PET scan as a negative control | Other: No drug or device, only a test. The test is called a PET/CT<br>* A single PET/CT scan will be performed<br>|
| Other: Tobacco cigarette smoker<br>Will undergo PET scan as a positive control | Other: No drug or device, only a test. The test is called a PET/CT<br>* A single PET/CT scan will be performed<br>|
| Other: E-cigarette user<br>Will undergo PET scan | Other: No drug or device, only a test. The test is called a PET/CT<br>* A single PET/CT scan will be performed<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| target-to-background ratio (TBR) | TBR will be detected on the scan | intraoperative | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
arterial inflammation, electronic cigarettes, PET scan
Imaging of Facial Neuritis

Study Overview
=================
Brief Summary
-----------------
Improved means of positive diagnosis of facial neuritis, the leading cause of peripheral facial palsy

Official Title
-----------------
Imaging of Facial Neuritis Using T2-weighted Gradient-echo Fast Imaging Employing Steady State Acquisition After Gadolinium Injection

Conditions
-----------------
Facial Neuritis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-80 years Subject giving their consent for their participation Patients with neuritis facial (neuritis group) who benefited, between 2009 and 2016, from an MRI of the internal auditory ducts, with gadolinous product injection and on the MRI 3 Tesla Patients with a perception deafness, without neuritis sign (control group) who also benefited from an MRI with gadolinous product injection on the MRI 3T with the same protocol. Exclusion Criteria: - Refusal to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence or absence of pathologic enhancement of the facial nerve on the symptomatological side of the T2 sequence (FIESTA-C) |  | 1 hour after the realization of the MRI | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
facial neuritis, T2 weighted gradient-echo, fast imaging employing steady state acquisition (FIESTA-C), magnetic resonance imaging (MRI)
Magnesium Versus High Dose Fentanyl in Endotracheal Intubation

Study Overview
=================
Brief Summary
-----------------
this study is designed to assess the efficacy of MgSO4 versus high dose fentanyl compared to conventional anesthesia in attenuating stress response to intubation

Detailed Description
-----------------
to assess the effect of MgSO4 combined with fentanyl compared to high dose fentanyl in attenuating stress response in cancer patients undergoing surgeries under general anesthesia requiring endotracheal intubation

Official Title
-----------------
Magnesium Versus High Dose Fentanyl in Attenuating Stress Response to Endotracheal Intubation

Conditions
-----------------
Stress Response

Intervention / Treatment
-----------------
* Drug: Magnesium sulfate- Fentanyl
* Drug: Fentanyl 4Mcg/kg
* Drug: Fentanyl 2Mcg/kg
* Drug: Lidocaine 1.5 mg/kg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cancer patients undergoing surgery under general anesthesia requiring endotracheal intubation ASA I II 18 to 60 Exclusion Criteria: allergy to any of the used drugs renal or hepatic impairment hypertensive patients, patients with cardiovascular or cerebrovascular diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Magnesium sulphate- Fentanyl<br>30 mg per kg MgSo4 infusion in 100 ml saline over 10 minutes | Drug: Magnesium sulfate- Fentanyl<br>* drug administration before intubation<br>* Other names: MgSo4;Drug: Fentanyl 2Mcg/kg<br>* drug administration with induction of anesthesia<br>* Other names: Conventional anesthesia;|
| Experimental: Fentanyl 4 mic<br>4 mic per kg fentanyl i.v | Drug: Fentanyl 4Mcg/kg<br>* drug administration with induction of anesthesia<br>* Other names: high dose fentanyl;|
| Active Comparator: Fentanyl<br>2 mic per kg fentanyl i.v | Drug: Fentanyl 2Mcg/kg<br>* drug administration with induction of anesthesia<br>* Other names: Conventional anesthesia;|
| Experimental: Lidocaine- Fentanyl<br>Lidocaine 1.5 mg/kg | Drug: Fentanyl 2Mcg/kg<br>* drug administration with induction of anesthesia<br>* Other names: Conventional anesthesia;Drug: Lidocaine 1.5 mg/kg<br>* drug administaration 90 sec before intubation<br>* Other names: Lidocaine;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| heart rate values | changes in heart rate values after intubation | 5 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blood pressure | mean arterial blood pressure values | 5 minutes | 
| coughing during intubation | coughing during intubation | lntubation time |
Etiology and Prevalence of Peripheral Arterial Disease

Study Overview
=================
Brief Summary
-----------------
To determine the prevalence of peripheral arterial disease in a defined population by non-invasive techniques; to evaluate the association of cardiovascular disease risk factors with peripheral vascular disease; to determine whether non-invasive tests of peripheral arterial disease can be utilized as markers for coronary heart disease; to determine the status of the microvasculature using conjunctival photographs and to compare the results with risk factors and the peripheral arterial disease testing results.

Detailed Description
-----------------
BACKGROUND: Atherosclerosis is frequently generalized, affecting blood vessels in various parts of the body. Previous studies had noted the strong association between peripheral arterial disease and coronary heart disease and the similarity of risk factors, particularly diabetes and cigarette smoking for both diseases. The natural history of peripheral arterial disease had not been delineated because of the lack, until recently, of accurate and reliable non-invasive testing. DESIGN NARRATIVE: All 624 subjects were initially studied under a Lipid Research Clinic protocol that involved two evaluations, visit 1 and visit 2. At visit 2, half of the subjects were from a random sample of the LRC visit 1 cohort and others were selected from the visit 1 cohort for hyperlipidemia, defined as being at or above age- and sex-specific 90th percentiles for cholesterol or 95th percentiles for triglycerides or taking lipid-lowering medications. At visit 2, the subjects were characterized as to age; sex; drug, diet, alcohol and smoking history; personal and family history of cardiovascular disease; Rose questionnaire; and electrocardiogram and examination by a cardiologist. The subjects were given a traditional manual examination for peripheral arterial disease and four non-invasive tests including segmental blood pressure, flow velocity by Doppler ultrasound, postocclusive reactive hyperemia, and pulse reappearance half-time. The subjects were categorized into large vessel peripheral arterial disease, isolated small vessel peripheral arterial disease or normal based on the results of non-invasive testing and followed for an average of four years. The study completion date listed in this record was obtained from the End Date entered in the Protocol Registration and Results System (PRS) record.

Conditions
-----------------
Cardiovascular Diseases, Peripheral Vascular Diseases, Arterial Occlusive Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Cardiometabolic Risk Factors Registry

Study Overview
=================
Brief Summary
-----------------
CARFARE (CARDIOMETABOLIC RISK FACTORS REGISTRY) is a registry done in the context of a cardiovascular primary prevention program of the Cardiometabolic Unit Officia of the Cardiology Department of the Austral University Hospital. The structured and sequential evaluation include measurement of anthropometric parameters (body mass index, BMI), laboratory with metabolic profile, baseline electrocardiogram, blood pressure (BP) measurement, arterial stiffness, subclinical atherosclerosis screening in the carotid and ileo-femoral territories using echo-doppler, echocardiogram, and ergometry test.

Official Title
-----------------
Cardiometabolic Risk Factors Registry

Conditions
-----------------
Atherosclerosis, Metabolic Syndrome, Diabetes, Cardiovascular Risk Factor, Cardiovascular Diseases, Obesity

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >18 years old. Exclusion Criteria: Previous cardiovascular and/or cerebrovascular event stable chronic angina advanced chronic kidney disease (Stage IV or V) cancer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of Major Adverse Cardiovascular Events (MACE) | Inicidence of myocardial infarction, stroke, unstable angina or acute heart failure | 5 years | 
| Mortality rate | Death due to MACE or other causes | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Subclinical Atherosclerosis, Metabolic Syndrome, Primary Prevention
Increase Surveillance for Breast and Ovarian Cancers, Also to Determine Targeted Risk-reducing and Preventative Strategies

Study Overview
=================
Brief Summary
-----------------
Observational study is to increase surveillance for breast and ovarian cancers, also to determine targeted risk-reducing and preventative strategies.

Detailed Description
-----------------
The general design of this study is collecting data and reviewing the Principal Investigators' (P.I.) Standard Operating Procedures (SOP) on BRCA testing and changes made to their specific SOP.

Official Title
-----------------
Medical Provider Experience Assessment Healthcare Decisions Post-Testing, Risk Reducing, and Preventative Strategies Using BRCA2 and BRCA2 Genetic Testing

Conditions
-----------------
Hereditary Cancer

Intervention / Treatment
-----------------
* Genetic: BRCA1 and BRCA2


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must be a Medical Practitioner Medical Doctor (MD) Doctor of Osteopathic (DO) Physician Assistant (PA) Advanced Practice Registered Nurse (APRN) Nurse Practitioner (NP) Must have a current standard operating procedure that includes obtaining/reviewing medical history and family medical history Exclusion Criteria: Government-funded insurance data cannot be included in the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: BRCA1 and BRCA2|Genetic breast and ovarian cancer testing|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Provider Structures and Processes | Plan of Care Changes due to BRCA testing. Provider based observational survey system on the health and well-being of patients and populations | 36 months |
Efficacy of Narrow Band Spectrum Endoscopy for the Diagnosis of Gastric Antral Vascular Ectasia in Patients With Liver Cirrhosis

Study Overview
=================
Brief Summary
-----------------
the study aims to evaluate the role of similar technology of Narrow Band Imaging VIST video intelligent staining technology in the diagnosis of Gastric Antral Vascular ectasia in cirrhotic patients

Detailed Description
-----------------
VIST (Video intelligent staining technology) is used to the diagnosis of GAVE as the form of ectatic vessels in the antrum in instead of erosions in the antrum by White light endoscopy which can mislead the diagnosis to Portal hypertension gastropathy. Targeted biopsies are taken and examined histopathologically in order to see if matching with VIST view. In addition, CD61 is used to highlight the diagnosis for more confirmation. CD61 is an immunohistochemistry platelets marker.

Official Title
-----------------
Efficacy of Narrow Band Spectrum Endoscopy Versus Histopathology for the Diagnosis of Gastric Antral Vascular Ectasia in Patients With Liver Cirrhosis

Conditions
-----------------
Gastric Antral Vascular Ectasia

Intervention / Treatment
-----------------
* Diagnostic Test: Upper gastrointestinal endoscopy and biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with mucosal vascular lesions at the gastric antrum suspicious of GAVE of a linear striped form or a diffuse punctate form upon conventional WLE Exclusion Criteria: Connective tissue disorders like systemic sclerosis. Chronic kidney disease. Recent use of proton pump inhibitors in the last 14 days. History of gastric surgery or gastric cancer. Pernicious anemia. Recent history of non-steroidal anti-inflammatory drugs intake

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Upper gastrointestinal endoscopy and biopsy|Gastroscope with technology of VIST video intelligent staining technology for taking biopsies|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy of Narrow Band Spectrum endoscopy for the diagnosis of Gastric antral vascular ectasia in cirrhotic patients | It is done by the new technology of VIST which is similar to Narrow Band Imaging in the diagnosis of Gastric antral vascular ectasia in cirrhotic patients that were misdiagnosed before as portal hypertension gastropathy | it is estimated to be 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Narrow Band
Comparison of Different Cardiac Output Measurement Methods in Patients Undergoing Right Heart Catheterization

Study Overview
=================
Brief Summary
-----------------
The objective of this observational study is to compare cardiac output evaluation by the Direct Fick method, Indirect Fick method and Thermodiluition in pulmonary hypertension (PH) patients undergoing right heart catheterization (RHC). The main questions it aims to answer are: Are these methods interchangeable? Can possible discrepancies influence risk stratification and therapeutic management of PH patients? All consecutive patients aged ≥18 years, referred for RHC for suspected PH, will be included. Exclusion criteria will be contraindications to RHC, cardiac shunts and failure to obtain informed consent. Patients will undergo RHC by a Swan-Ganz catheter through the right internal jugular vein ultrasound-guided cannulation and cardiac output will be calculated using the three above-mentioned methods.

Official Title
-----------------
Cardiac Output Assessment in Pulmonary Hypertension Patients Undergoing Right Heart Catheterization

Conditions
-----------------
Pulmonary Hypertension

Intervention / Treatment
-----------------
* Diagnostic Test: right heart catheterization


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥18 years Suspected pulmonary hypertension at clinical and echocardiographic evaluation Exclusion Criteria: contraindication to Right Heart Catheterization (RHC) cardiac shunt inability to provide informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients undergoing right heart catheterization<br> | Diagnostic Test: right heart catheterization<br>* Right heart catheterization (RHC) is an invasive hemodynamic procedure that allows direct measurement of right-sided cardiac pressures, calculation of cardiac output and pulmonary vascular resistance. It is the gold standard for the diagnosis of pulmonary arterial hypertension. Right heart catheterization is commonly performed by accessing the internal jugular vein (echo-guided access). Swan Ganz catheter with a dedicated thermistor is used to perform RHC; it is advanced through the right heart chambers to measure right atrial, right ventricle, pulmonary artery and pulmonary arterial wedge pressures. Cardiac output is measured using Fick direct, Fick indirect and thermodilution methods.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| differences in cardiac output values measured using three different methods (Direct Fick, Indirect Fick and Thermodiluition) | In all patients cardiac output will be measured using the three methods to evaluate if the values obtained significantly differ | through study completion, an average of 1 year |